Originally Posted by
trader_jackson
Interesting we are talking about high PE for ARV (we won't bother looking at other metrics like highest dividend yield or cheapest price to book) - some say SUM is on 14.2x 2019 forward PE, OCA on 14.3x 2019 foward PE, and... ARV on a 13.9x 2019 forward PE (that was before todays bigly results were released - probably lower now after the impending concensus upgrade around full year profits)... RYM on 25.3 and MET on 13.1 but nobody cares about that - one has always been wildy overvalued while the other has unknown remedial costs and all sorts of not so great stuff
Looking at FY20, well the three horses above, sorry, 2 stallions and a dog, are pretty close (all in the mid 12's)... wow 4 years ago if anybody had tried to remotely see ARV in the same light as others listed at the time, it would have been meet with nothing but laughter
2H likely to be softer than previous years (relative the first half) but probably a record and FY19 ARV on track to beat the famed ryman in terms of underlying EPS growth, maybe even come dangerously close to sum others (how embarrassing that could/would/might be!)
After RYM, the market leader as we all know, posted a NPAT drop, I got a bit worried (market didn't really care) ARV would do the same (it did a year back), but no... quite the opposite... and NPAT is the thing that counts the most isn't it?
Tomorrow I reckon Forsyth gonna say $1.75, a record 12 month price target from them for ARV... but we all know it'll probably struggle to stay above $1.30, too much attention going to OCA for anybody to notice ARV